Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia (NCT04779242), a randomized phase 3 study. The primary outcome is Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit.

2. Clinical Question

The clinical question is therefore a comparison between two active antibiotic regimens in adults with community-acquired bacterial pneumonia, using an early symptom-based response measure. The endpoint is not simply a report of feeling better: the registry definition incorporates survival, change from baseline in multiple symptoms, and absence of symptom worsening. It also treats alternative antibacterial treatment for CABP, certain discontinuations, and death as clinical failure. An indeterminate response is separately defined for participants whose response could not be inferred because they were not assessed for a specified reason.

The record describes randomized allocation and triple masking. It does not report numerical primary-endpoint results or a single reduced comparison across the endpoint's categories or time points. Consequently, the clinical question can be described, but the posted record does not establish which regimen had a higher early-response percentage or how precisely any difference was estimated.

3. Trial Design

This was a Phase 3b randomized, double-blind, multi-center, parallel-group study comparing intravenous and oral omadacycline with intravenous and oral moxifloxacin for adult community-acquired bacterial pneumonia. The trial is recorded as completed, with enrollment of 670. The listed start date is 2021-02-25 and the primary completion date is 2024-03-27. Paratek Pharmaceuticals Inc is identified as the sponsor.

In a randomized study, allocation by chance is intended to make the comparison less dependent on clinicians' or participants' choices. Randomization does not guarantee that the groups will be identical in every characteristic, but it provides a basis for comparing outcomes under the assigned study regimens. The parallel design means participants were assigned to one study arm rather than crossing between the two regimens.

The registry identifies masking as triple, but it does not identify in the record which specific roles were masked or how masking was maintained. The study is described as double-blind in its official title; further details about masking procedures are not reported in the registry record. The route options and duration are listed for both arms, but details about how the route was selected or changed are not reported in the registry record.

The registered primary outcome is the percentage of participants with early clinical response at the ECR visit, assessed 72 to 120 hours after the first dose. The record also lists investigator-assessed clinical response at the post-therapy evaluation visit and an analysis in the clinically evaluable post-therapy population. These are separate outcome descriptions and populations; their results should not be treated as interchangeable with the ITT primary endpoint.

The record does not report the sample-size justification, the planned statistical model, interim analyses, or a detailed analysis plan. The enrollment figure describes the trial record, not the number of participants with an observed primary outcome in each arm. Arm-specific outcome denominators are not reported for the primary endpoint.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 670 participants were enrolled in approximately 75 sites globally.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: ITT population

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Intent-to Treat (ITT) population consisted of all randomized participants regardless of whether or not the participant received test article.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit, measured over 72 to 120 hours after the first dose of test article.

The primary endpoint is the percentage of participants with early clinical response at the early clinical response (ECR) visit. The visit is specified as occurring 72 to 120 hours after the first dose of study treatment. The primary population is the ITT population.

Under the registry definition, early clinical response is clinical success: the participant must be alive and show improvement of at least 1 level from baseline in at least 2 CABP symptoms, with no worsening in CABP symptoms. The symptoms named are cough, sputum production, pleuritic chest pain, and dyspnea. Investigators assess symptom severity on a 4-point scale: absent, mild, moderate, or severe. The response is determined programmatically using the investigator's symptom assessments.

The definition also makes clear that response is not determined by symptom improvement alone. Clinical failure includes lack of the required improvement, worsening symptoms, alternative antibacterial treatment for CABP, discontinuation due to an adverse event requiring alternative antibacterial treatment, or death. An indeterminate response is described when the participant was not assessed because of withdrawal of consent or another specified reason, leaving response impossible to infer adequately.

As a percentage endpoint, the measure describes the proportion of the analyzed population classified as having the specified response, subject to the registry's outcome-category handling. Such an endpoint is useful for asking whether early clinical improvement is observed across multiple symptoms during the early treatment period. The record does not report the primary endpoint's arm-level percentages, category counts, or an estimated comparison.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

General statistical explanation: A clinical trial comparison uses outcome data from participants assigned to each study arm to estimate how outcomes differ between the assigned regimens. Randomization supports this comparison by reducing systematic differences in treatment assignment, while masking can reduce the influence of expectations on care or outcome assessment. These design features do not by themselves reveal the size or precision of an outcome difference; those require the observed results and their analysis.

What does a percentage endpoint describe?

The primary measure is a percentage of participants classified as having early clinical response. In general, a percentage is a proportion expressed on a percentage scale: it relates the number meeting an outcome definition to the number included in the relevant denominator. The denominator is important because the same percentage can have different precision in groups of different sizes. The primary endpoint is specified for the ITT population, but arm-specific denominators and outcome counts are not reported in the registry record.

The response classification combines several requirements. It includes survival, improvement relative to baseline in multiple symptoms, and no symptom worsening. The source assessments use a 4-point symptom severity scale. The endpoint also distinguishes clinical failure from an indeterminate response. This means the data are not merely a continuous measure of symptom severity; they are translated into categories according to the stated rules. The registry record does not provide the category counts or a full description of how indeterminate responses were handled in the reported analysis.

Why does an interval matter?

General statistical explanation: A confidence interval expresses the precision of an estimate under a statistical model. A narrow interval indicates more precision than a wide interval, while both the estimate and interval are needed to understand the range of effects compatible with the data and model. An interval does not eliminate uncertainty or prove that the true effect lies within its limits with certainty. Primary endpoint estimates and confidence intervals are not reported in the registry record, so precision cannot be evaluated for that comparison.

Likewise, a p-value addresses compatibility between observed data and a specified null hypothesis under an analysis model; it is not the probability that a treatment is effective or that the null hypothesis is true. A p-value alone would not convey the size of an effect or its clinical importance. The record does not report a primary-endpoint p-value or a specific statistical test, so none should be inferred.

What can randomization and masking support?

General statistical explanation: Random allocation aims to make treatment groups comparable, on average, with respect to both measured and unmeasured baseline characteristics. It is not a guarantee of exact balance in a particular trial. Masking is intended to limit expectations from affecting treatment decisions, participant reporting, or assessments. Here, the registry records randomized allocation and triple masking, while the official title describes the study as double-blind. Specific masked roles and operational procedures are not reported in the registry record.

The parallel design compares groups followed under their assigned regimen rather than comparing each participant with themself under both regimens. The primary population is identified as ITT. In general, an ITT approach analyzes participants according to randomized assignment, regardless of subsequent treatment changes, though exact implementation depends on the analysis plan. The registry does not report enough detail to determine the precise handling of missing outcomes, protocol deviations, or treatment discontinuations in the primary analysis.

How should planning estimates be understood?

General statistical explanation: A sample-size planning illustration asks how many participants might be needed under assumptions about an effect, significance level, allocation, and statistical approximation. The record describes planning assumptions of a two-sided significance level of 0.05, equal allocation, and a normal approximation, with a target effect defined as a stated fraction of the observed effect. Such figures are planning illustrations, not observed power and not evidence about the trial's results. No numerical planning estimate is reported in the registry record for a single primary comparison; the outcome entry has several categories or time points and is not reduced to one comparison.

For a binary outcome, a planning calculation depends on the assumed response rates or effect and the method used to compare them. If the observed effect is used as a starting point, the resulting illustration is conditional on that effect and may not represent a future trial's true effect. A separate planning row based on a fraction of the effect explores a smaller target effect, but no particular fraction or numerical sample-size value is stated in the registry record.

Why do analysis populations matter?

The primary endpoint is defined for the ITT population. The secondary outcomes include investigator assessment at the post-therapy evaluation visit and a clinically evaluable post-therapy population analysis. In general, a clinically evaluable population may include participants meeting specified evaluability criteria, while an ITT population is tied to randomized assignment. Because populations can differ in membership and purpose, results across them may answer different questions. The record does not report the eligibility rules for the clinically evaluable analysis or the exact analysis populations used for each outcome.

Finally, adverse-event counts are descriptive safety information, not a statistical substitute for efficacy outcomes. In general, safety interpretation depends on definitions, follow-up, exposure, denominators, and how events are collected and coded. The registry lists group counts and selected serious-event terms, but further collection and analysis details are not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary early clinical response outcome and secondary investigator-assessed clinical response outcomes at the post-therapy evaluation visit. It does not report whether or how the statistical plan controlled the chance of false-positive findings across multiple outcomes, analyses, time points, or populations. Adjustment procedures, a testing hierarchy, and a prespecified order of interpretation are not reported in the registry record. Accordingly, no claim about multiplicity control can be made.

The primary outcome entry is not reduced to a single comparison because it has several categories or time points. The record describes clinical success, clinical failure, and indeterminate response, but does not report their counts or a single numerical comparison. The exact statistical treatment of those categories is not reported in the registry record.

The primary population is the ITT population. The secondary outcomes include a clinically evaluable post-therapy population. The registry record does not provide detailed membership criteria for the clinically evaluable population or state how participants were handled across each analysis population.

Missing-data rules are not reported in the registry record. In particular, the record does not specify an imputation method, a sensitivity analysis, or how unobserved ECR assessments were treated in the numerical analysis. The outcome definition identifies an indeterminate response when a participant was not assessed because of withdrawal of consent or another specified reason, but that definition alone does not establish how such cases were included in statistical calculations.

These omissions limit assessment of the robustness of any comparison. Without outcome counts, analysis populations, missing-data procedures, and multiplicity details, the registry descriptions are not enough to reconstruct the primary analysis or evaluate whether secondary findings were exploratory or confirmatory.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cardiac failure (0.6%), cardiac arrest (0.6%), pneumonia (0.6%), covid-19 (0.6%), acute respiratory failure (0.6%).

The safety entry reports serious adverse events, other adverse events, and deaths separately for the two arms. In the omadacycline group, 17 participants were affected by serious adverse events among 336 at risk, 32 were affected by other adverse events among 336 at risk, and 6 deaths were reported. In the moxifloxacin group, 15 participants were affected by serious adverse events among 332 at risk, 36 were affected by other adverse events among 332 at risk, and 6 deaths were reported.

The serious-event terms listed include cardiac failure, cardiac arrest, pneumonia, COVID-19, acute respiratory failure, and cardiopulmonary failure. The record gives 0.6% for each of the first five terms and 0.3% for cardiopulmonary failure. These are reported term percentages; the record does not specify further details about event-level counts, overlap between terms, or the attribution of events to treatment.

These entries are descriptive safety figures. A participant may have experienced more than one event, and the record does not establish from these summaries whether event categories overlap. The counts alone do not determine whether an event was caused by study treatment. They also do not provide an adjusted comparison or confidence intervals. The numbers should therefore be read as recorded safety summaries, not as proof of a difference in risk between the regimens.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a randomized, masked, parallel-group trial compared omadacycline with moxifloxacin in adults with community-acquired bacterial pneumonia. It also defines an early clinical response outcome and reports selected safety counts. Those details describe what the study set out to compare and what outcome definitions it used.

The record does not report numerical primary-endpoint findings. It therefore does not show the percentage with early clinical response in either arm, the size or direction of an estimated difference, or the uncertainty around that estimate. There is no basis in the recorded primary outcome information for saying which regimen had a higher response percentage or whether any observed difference was precise.

The primary response definition combines survival and changes in several symptoms. It also includes conditions that classify a participant as a clinical failure and a separate indeterminate category. The distinction between these categories is important: a numerical response estimate depends on how outcomes were classified and how missing or indeterminate assessments were handled. Those numerical details and analysis procedures are not reported in the registry record.

The safety summaries report counts for serious adverse events, other adverse events, and deaths. They are useful descriptions of the safety information recorded for each arm, but they are not evidence on their own that a regimen caused or prevented an event. The listed serious-event term percentages do not replace a complete safety analysis or the primary efficacy comparison.

In general, trial conclusions depend on the estimated effects, their precision, the analysis population, and the methods used to address missing data and multiple outcomes. Those elements are not fully available in the registry record. The appropriate interpretation is therefore limited to the study design, endpoint definitions, and safety summaries that are recorded, without concluding that either regimen was superior, equivalent, or ineffective.

13. Why This Trial Matters Statistically

This trial illustrates why a statistical reading of a randomized study requires more than knowing the treatment groups and enrollment. Randomization and masking describe important design features, but the primary question ultimately depends on the observed outcome distribution, the comparison between groups, and the precision of that comparison. The registry record describes the intended early clinical response measure but does not report its numerical results.

The endpoint also shows how outcome definitions shape interpretation. Early response is not a single symptom score: it requires survival, improvement in multiple CABP symptoms, and no worsening. Clinical failure includes treatment-related circumstances and death, while an indeterminate category addresses assessments that could not be inferred. Clear definitions help readers understand the target outcome, but category counts and analysis rules are needed to assess how the definition was applied in the results.

The distinction between ITT and clinically evaluable populations is also statistically important. Different analysis populations can represent different estimands and may be affected differently by missing assessments or exclusions. The primary endpoint is identified with the ITT population, while a secondary outcome uses a clinically evaluable population. The record does not provide enough detail to examine the relationship between those analyses.

Finally, the safety summaries demonstrate the difference between descriptive reporting and comparative inference. Counts and term percentages convey recorded events, but without the full analysis, uncertainty, and event-handling detail, they cannot alone establish a treatment-related difference. The missing numerical primary results are a central limitation: design information helps frame a trial, but it cannot answer the efficacy comparison without reported estimates.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important trial-specific limitation in the registry record is the absence of numerical primary-endpoint results. The endpoint is described, but arm-specific percentages, outcome counts, denominators, an estimated comparison, and confidence intervals are not reported in the registry record. This prevents assessment of effect direction, magnitude, and precision.

The primary outcome entry is not reduced to one comparison because it has several categories or time points. The description distinguishes clinical success, failure, and indeterminate response, but the numerical distribution among these categories is not recorded. The handling of indeterminate responses in the primary analysis is not reported in the registry record.

The record identifies the ITT population for the primary endpoint and lists a clinically evaluable population for a secondary outcome. It does not give the detailed criteria for the latter population, the exact analyzed denominators, or the handling of participants with missing assessments. Missing-data procedures and sensitivity analyses are not reported in the registry record.

The record also does not report the sample-size justification, detailed statistical analysis plan, multiplicity procedures, or interim analyses. While planning assumptions are described, no numerical planning estimate is reported for a single primary comparison. The primary outcome's multiple categories or time points make it inappropriate to infer a single comparison from the endpoint description alone.

Safety information is limited to the listed counts and selected serious-event terms. Further details about event overlap, exposure, ascertainment, and treatment attribution are not reported in the registry record. These limitations restrict both efficacy interpretation and assessment of the comparative safety summaries.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia — NCT04779242.
• Registry record last updated 2025-04-09; status last verified 2025-03.
• Results first posted 2025-04-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT04779242 is a completed Phase 3b randomized, double-blind, multi-center, parallel-group trial sponsored by Paratek Pharmaceuticals Inc. It enrolled 670 participants and compared intravenous/oral omadacycline with intravenous/oral moxifloxacin for adult community-acquired bacterial pneumonia. The listed trial start date is 2021-02-25 and primary completion date is 2024-03-27.

The primary outcome is the percentage of participants with early clinical response at 72 to 120 hours after the first dose, in the ITT population. The registry defines response through survival and improvement in multiple CABP symptoms without worsening. Numerical results for this endpoint are not reported in the registry record.

The record lists post-therapy investigator-assessed secondary outcomes and descriptive safety counts, including serious adverse events, other adverse events, and deaths. It does not report the detailed statistical plan, missing-data procedures, or multiplicity approach.